GTA5

Why Covishield dose gap must be shortened

Two studies were cited mainly for increasing the interval. In a Lancet study published earlier this year, efficacy result in phase-3 clinical trial of two doses of Oxford-AstraZeneca (Covishield equivalent) was 55.1% when the second dose was given in less than six weeks. This result was from a combined analysis of the participants from the United Kingdom, Brazil and South Africa. They indicated that the efficacy was 81.3% when the dosing interval stretched to 12 weeks or more. Next, AstraZeneca published interim results from phase-3 clinical trials in participants from the United States in March 2021, showing vaccine efficacy of 76% against symptomatic Covid-19 when the interval between doses was four weeks.

Read the full article on TOI+ Opinion: Why 2nd dose time must be shortened

 



Linkedin


Disclaimer

Views expressed above are the author’s own.



END OF ARTICLE



Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close
Close